0 11 Cyclosporin Cyclosporin NNP 12 23 A-resistant a-resistant JJ 24 39 transactivation transactivation NN 40 42 of of IN 43 46 the the DT 47 51 IL-2 il-2 NN 52 60 promoter promoter NN 61 69 requires require VBZ 70 78 activity activity NN 79 81 of of IN 82 89 okadaic okadaic JJ 90 104 acid-sensitive acid-sensitive JJ 105 121 serine/threonine serine/threonine NN 122 134 phosphatases phosphatas NNS 134 135 . . . 137 147 Expression expression NN 148 150 of of IN 151 154 the the DT 155 159 IL-2 il-2 NN 160 164 gene gene NN 165 173 requires require VBZ 174 184 activation activation NN 185 187 of of IN 188 189 T t NN 190 195 cells cell NNS 196 203 through through IN 204 215 stimulation stimulation NN 216 218 of of IN 219 222 the the DT 223 226 TCR TCR NNP 227 230 and and CC 231 244 costimulation costimulation NN 245 252 through through IN 253 262 accessory accessory NN 263 272 receptors receptor NNS 272 273 . . . 274 276 We we PRP 277 281 have have VBP 282 287 found find VBN 288 296 recently recently RB 297 301 that that IN 302 309 okadaic okadaic JJ 310 324 acid-sensitive acid-sensitive JJ 325 332 Ser/Thr Ser/Thr NNP 333 345 phosphatases phosphatas NNS 346 349 are be VBP 350 358 involved involve VBN 359 361 in in IN 362 363 a a DT 364 375 cyclosporin cyclosporin NN 376 389 A-insensitive a-insensitive JJ 390 397 pathway pathway NN 398 402 that that WDT 403 414 selectively selectively RB 415 424 transmits transmit VBZ 425 438 costimulatory costimulatory JJ 439 446 signals signal NNS 446 447 . . . 448 450 In in IN 451 455 this this DT 456 461 study study NN 461 462 , , , 463 465 we we PRP 466 474 analyzed analyze VBD 475 482 whether whether IN 483 493 activities activity NNS 494 496 of of IN 497 502 these these DT 503 515 phosphatases phosphatas NNS 516 519 are be VBP 520 529 necessary necessary JJ 530 533 for for IN 534 537 the the DT 538 548 expression expression NN 549 551 of of IN 552 555 the the DT 556 560 IL-2 il-2 NN 561 565 gene gene NN 565 566 . . . 567 569 In in IN 570 574 both both CC 575 584 activated activate VBN 585 595 peripheral peripheral JJ 596 601 blood blood NN 602 603 T t NN 604 615 lymphocytes lymphocyte NNS 616 619 and and CC 620 629 activated activate VBN 630 641 tumorigenic tumorigenic JJ 642 643 T t NN 644 648 cell cell NN 649 654 lines line NNS 654 655 , , , 656 660 IL-2 il-2 NN 661 665 gene gene NN 666 676 expression expression NN 677 680 was be VBD 681 688 blocked block VBN 689 691 at at IN 692 695 the the DT 696 711 transcriptional transcriptional JJ 712 717 level level NN 718 720 by by IN 721 728 okadaic okadaic JJ 729 733 acid acid NN 733 734 . . . 735 738 The the DT 739 752 transcription transcription NN 753 760 factors factor NNS 761 767 active active JJ 768 770 at at IN 771 774 the the DT 775 779 IL-2 il-2 NN 780 788 promoter promoter NN 789 793 were be VBD 794 808 differentially differentially RB 809 819 influenced influence VBN 819 820 : : : 821 825 upon upon IN 826 841 down-modulation down-modulation NN 842 844 of of IN 845 852 okadaic okadaic JJ 853 867 acid-sensitive acid-sensitive JJ 868 880 phosphatases phosphatas NNS 880 881 , , , 882 897 transactivation transactivation NN 898 900 by by IN 901 908 octamer octamer NN 908 909 , , , 910 918 NF-kappa NF-kappa NNP 919 920 B B NNP 920 921 , , , 922 925 and and CC 926 928 NF NF NNP 929 931 of of IN 932 941 activated activate VBN 942 943 T t NN 944 949 cells cell NNS 950 958 proteins protein NNS 959 962 was be VBD 963 972 abrogated abrogate VBN 972 973 , , , 974 979 while while IN 980 995 transactivation transactivation NN 996 998 by by IN 999 1003 AP-1 ap-1 NN 1004 1012 proteins protein NNS 1013 1016 was be VBD 1017 1021 even even RB 1022 1030 enhanced enhance VBN 1030 1031 . . .